These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 7512895)

  • 21. Central zone carcinoma of the prostate gland: a distinct tumor type with poor prognostic features.
    Cohen RJ; Shannon BA; Phillips M; Moorin RE; Wheeler TM; Garrett KL
    J Urol; 2008 May; 179(5):1762-7; discussion 1767. PubMed ID: 18343454
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Substaging pathologically organ confined (pT2) prostate cancer: an exercise in futility?
    van der Kwast TH
    Eur Urol; 2006 Feb; 49(2):209-11. PubMed ID: 16417961
    [No Abstract]   [Full Text] [Related]  

  • 23. The case against extended lymph-node dissection for prostate cancer.
    Huland H
    Nat Clin Pract Urol; 2006 Sep; 3(9):456-7. PubMed ID: 16964181
    [No Abstract]   [Full Text] [Related]  

  • 24. Prostate specimen reevaluation in patients with organ confined prostate cancer and postoperative biological recurrence.
    Ravery V; De la Taille A; Toublanc M; Boccon-Gibod L; Hermieu JF; Delmas V; Boccon-Gibod L
    J Urol; 1996 Jun; 155(6):1981-2. PubMed ID: 8618302
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Pathological outcomes and biochemical progression in men with T1c prostate cancer undergoing radical prostatectomy with prostate specific antigen 2.6 to 4.0 vs 4.1 to 6.0 ng/ml.
    Makarov DV; Humphreys EB; Mangold LA; Walsh PC; Partin AW; Epstein JI; Freedland SJ
    J Urol; 2006 Aug; 176(2):554-8. PubMed ID: 16813888
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Re: The prostate specific antigen era in the United States is over for prostate cancer: what happened in the last 20 years?
    Rosser CJ; Parker A
    J Urol; 2005 Sep; 174(3):1154-5; author reply 1155-6. PubMed ID: 16094093
    [No Abstract]   [Full Text] [Related]  

  • 27. [Staging of prostatic cancer before and after radical prostatectomy].
    Pushkar' DIu; Bernikov AN; Bormotin AV
    Urologiia; 2003; (4):60-8. PubMed ID: 12942732
    [No Abstract]   [Full Text] [Related]  

  • 28. [The role of radical prostatectomy in cT3 prostate carcinoma].
    Van Poppel H; Goethuys H; Callewaert P; Vanuytsel L; Van de Voorde W; Baert L
    Praxis (Bern 1994); 2001 Sep; 90(38):1623-31. PubMed ID: 11675915
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Do close but negative margins in radical prostatectomy specimens increase the risk of postoperative progression?].
    Wirth M
    Urologe A; 1998 Jul; 37(4):427-8. PubMed ID: 9738298
    [No Abstract]   [Full Text] [Related]  

  • 30. Preoperative prediction of small volume cancer (less than 0.5 ml) in radical prostatectomy specimens.
    Cheng L; Poulos CK; Pan CX; Jones TD; Daggy JK; Eble JN; Koch MO
    J Urol; 2005 Sep; 174(3):898-902. PubMed ID: 16093983
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [The value of prostate-specific antigen in therapy follow-up of prostatic carcinoma].
    Wirth MP; Pilarsky C
    Urologe A; 1995 Jul; 34(4):297-302. PubMed ID: 7545844
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Postoperative pathomorphologic classification of prostate cancer. Recommendations for the processing of total prostatectomies and relevance of the findings].
    Kastendieck H; Hüsselmann H
    Pathologe; 1982 Sep; 3(5):278-86. PubMed ID: 7145866
    [No Abstract]   [Full Text] [Related]  

  • 33. Regional hyperthermia in conjunction with definitive radiotherapy against recurrent or locally advanced prostate cancer T3 pN0 M0.
    Tilly W; Gellermann J; Graf R; Hildebrandt B; Weissbach L; Budach V; Felix R; Wust P
    Strahlenther Onkol; 2005 Jan; 181(1):35-41. PubMed ID: 15660191
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Prostate cancer.
    Schlegel PN
    Curr Ther Endocrinol Metab; 1994; 5():543-50. PubMed ID: 7535663
    [No Abstract]   [Full Text] [Related]  

  • 35. [A case report: mucinous carcinoma of prostate].
    Noma M; Mori N; Kobayashi Y; Hara T; Yamaguchi S
    Hinyokika Kiyo; 2003 Oct; 49(10):591-3. PubMed ID: 14655602
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Treatment option for pT3 patient after radical prostatectomy].
    Sugimura Y; Wakita T; Mizogam A
    Hinyokika Kiyo; 2005 Sep; 51(9):571-3. PubMed ID: 16229368
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Is radiotherapy useful in node-positive prostate cancer patients after radical prostatectomy?
    Van Poppel H
    Eur Urol; 2009 May; 55(5):1012-3. PubMed ID: 19261377
    [No Abstract]   [Full Text] [Related]  

  • 38. [Radical perineal prostatectomy].
    Fichtner J; Stackl W; Thüroff JW
    Aktuelle Urol; 2008 Sep; 39(5):381-94. PubMed ID: 18798129
    [No Abstract]   [Full Text] [Related]  

  • 39. Management of prostate carcinoma.
    Whitehead ED
    N Y State J Med; 1981 Sep; 81(10):1481-5. PubMed ID: 7024862
    [No Abstract]   [Full Text] [Related]  

  • 40. An extended pelvic lymph-node dissection should be performed in most patients if radical prostatectomy is truly indicated.
    Burkhard FC; Schumacher MC; Studer UE
    Nat Clin Pract Urol; 2006 Sep; 3(9):454-5. PubMed ID: 16964180
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.